Antimicrobial agents

US11052137B2 · kind B2 · utility

Assignees

• LYSANDO AG · LI
• Katholieke Universiteit Leuven, KU LEUVEN R&D · BE

Inventors

• Rob Lavigne · Ekeren, BE
• Stefan Miller · Regensburg, DE
• Yves Briers · Fribourg, CH
• Guido Volckaert · Holsbeek, BE
• Maarten Walmagh · Herk-de-Stad, BE

Key dates

• Filing date: Oct 24, 2018
• Grant date: Jul 6, 2021
• Expiry date: Nov 29, 2038

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.